Company / Revenue per Share
Adaptimmune Therapeutics PLC Revenue per Share History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue per Share
$0.13
FY2024
5-year range
$0.01 / $0.13
FY2020-FY2024
Trend
+113.9%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Revenue per Share has increased for 5 consecutive years, from $0.00 in FY2019 to $0.13 in FY2024.
Based on SEC 10-K filings.
0.13 in FY2024 with a 5-year CAGR of +135.9%.
Improved from $0.03 to $0.13 over the past 2 years.
Revenue per Share over time
Growth rates
- 3-Year CAGR
- +170.2%
- 5-Year CAGR
- +135.9%
- 10-Year CAGR
- -
Key checks
Key Insights
- Adaptimmune Therapeutics PLC's revenue per share has grown for 5 consecutive years.
- In FY2024, revenue per share increased 113.9% year-over-year.
- Lowest revenue per share in the period was in FY2019.
Company context
Key Data Points
- Altman Z-Score -3.53 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Revenue per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $0.13 | +113.9% |
| FY2023 | $0.06 | +108.9% |
| FY2022 | $0.03 | +341.6% |
| FY2021 | $0.01 | +5.6% |
| FY2020 | $0.01 | +250.8% |
| FY2019 | $0.00 | -98.3% |
| FY2018 | $0.11 | +18.9% |
| FY2017 | $0.09 | +166.4% |
| FY2016 | $0.03 | - |
As of FY2024 · SEC 10-K · Updated Jun 29, 2026